Viracor has extensive experience performing pathogen load monitoring, antiviral resistance assessment, nucleic acid sequencing and other pathogen characterizations for clinical trials.
With a wide range of viral and bacterial targets, you have access to a comprehensive menu of real-time PCR and sequencing assays for pathogen detection and monitoring. Viracor’s multiple-target, dual gene assays, an approach we adopted early in the transition to molecular diagnostics, are designed to eliminate false negative results or under-quantification.
As experts in infectious disease assays, we offer a broad array of testing solutions for biomarker detection, immunogenicity, and other safety and efficacy assessments to support anti-viral and vaccine candidate clinical programs.
We also offer validated molecular and serology tests for SARS-CoV-2, along and other bioassay solutions that are helping our clients COVID-19 vaccine and anti-viral therapy development efforts.
Viracor offers clients a wealth of infectious disease testing options for clinical studies, including:
Additional Chronic Viral Infection Testing: